Recombinant hemagglutinin protein vaccine: a new option in immunization against influenza

Influenza continues to be a major cause of morbidity and mortality worldwide. Vaccination is the most effective strategy to prevent influenza complications. Traditional influenza vaccines rely on an egg-based production system that has several limitations like dependence on egg supply, long producti...

Full description

Saved in:
Bibliographic Details
Published inFuture virology Vol. 10; no. 9; pp. 1057 - 1067
Main Authors Gutierrez, Andres F, Sahly, Hana El
Format Journal Article
LanguageEnglish
Published London Future Medicine Ltd 01.09.2015
Subjects
Age
Antigens
baculovirus
Biotechnology industries
Cell culture
Clinical trials
Complications and side effects
egg allergy
Eggs
Fibroblasts
Health care
hemagglutinin
Hepatitis
Immunization
Infections
Influenza
Influenza vaccines
Lectins
Mortality
Names
Prevention
Proteins
Public health
recombinant vaccine
United States
Vaccination
Vaccines
Viruses
United States
Online AccessGet full text

Cover

More Information
Summary:Influenza continues to be a major cause of morbidity and mortality worldwide. Vaccination is the most effective strategy to prevent influenza complications. Traditional influenza vaccines rely on an egg-based production system that has several limitations like dependence on egg supply, long production time and contraindication in people with severe egg allergy. Alternative vaccine production systems are then necessary. The insect cell-baculovirus-based production technology has shown the ability to overcome these limitations. A recombinant trivalent hemagglutinin vaccine (RIV3 - Flublok ) produced using this system is available and licensed in the USA since 2013 for use in adults. This is the first vaccine to contain recombinant influenza virus proteins, with a hemagglutinin concentration that is three-times the one found in inactivated influenza vaccine. Different studies have shown that RIV3 is well tolerated, immunogenic and efficacious, thus proving it to be an additional option for immunization against influenza in adults.
ISSN:1746-0794
1746-0808
DOI:10.2217/fvl.15.75